Kornimate/medical-research-clean huggingface dataset:
factors associated with the risk of post tonsillectomy hemorrhage

Conditions: Bleeding Following Tonsillectomy (Disorder)

Summary: factors associated with increase risk of post tonsillectomy hemorrhage and score of associated factors

investigators review the medical records of patients who underwent tonsillectomy with or without adenoidectomy in our facility. none of the included patients had any known coagulopathy. the surgery was performed by several different surgeons, either otolaryngology residents or specialists, and using either cold or bipolar dissection. the procedures were performed under general anesthesia with orotracheal intubation. bipolar electrocoagulation was used for hemostasis, as well as in some cases vicryl sutures. all medical records were reviewed according to age, gender, indications for tonsillectomy (tonsil hypertrophy causing upper airway obstruction, snoring or sleep apnea, chronic tonsillitis, peritonsillar abscess or suspected malignancy of the tonsils), coagulation profile \[international normalized ratio (inr) and activated partial thromboplastin time values (aptt)\], type of surgery (tonsillectomy alone or adenotonsillectomy), surgical technique (cold or bipolar dissection), hemostasis method (bipolar electrocoagulation alone or electrocoagulation and sutures) and post-operative hemorrhage and its characterization. in this report, investigators will evaluate patients and collection of data to make a new scoring system that assesses patients according to several preoperative and postoperative factors to know the possibility of patients developing post tonsillectomy hemorrhage. post tonsillectomy hemorrhage is divided into two groups according to its severity: minimal hemorrhage that stopped spontaneously/after noninvasive treatment, and hemorrhage requiring reoperation for hemostasis revision in the operating room under general anesthesia. postoperative hemorrhage was defined as any bleeding requiring in hospital observation or treatment (medical, compression, cauterization under general anesthesia). patients who did not seek medical attention (e.g., patients with blood-tinged sputum or only minor bleeding) were not included in the group with post-operative hemorrhage

Eligibility criteria:
* inclusion criteria : all cases complicated by post-tonsillectomy bleeding 1. after elective or emergency tonsillectomy 2. primary hge or secondary hge 3. regardless of age, the indication of surgery, surgical techniques * exclusion criteria: 1. patient who have preoperative inherited bleeding disorder 2. patients who did not seek medical attention (e.g., patients with blood-tinged sputum or only minor bleeding) riteria:
first in man evaluation of single and multiple doses of oral atx2417

Conditions: Allergy

Summary: first in man evaluation of single and multiple doses of compound atx2417 in healthy male volunteers. a double blind placebo controlled parallel group ascending dose design; up to five dose levels for the single dose and up to two dose levels for the multiple dose (8 days of dosing). subjects will be screened to assure normal health prior to inclusion in the trial and will be monitored for safety (adverse events, vital signs, ecgs, safety labs) and pharmacokinetic profile. a fasted/fed comparison will also be included in the single ascending dose part of the trial.

the study consists of two parts, a (single ascending dose including fasted/fed comparison) and b (multiple ascending dose). part b will be conducted after a thorough review by the sponsor and the principal investigator of the data arising from part a. part a this will be a randomised, double blind, placebo controlled, parallel group titration of up to seven single dose levels of atx2417. in each cohort, six subjects will receive active compound and two will receive placebo in a randomised fashion. at each dose level, 2 subjects (1 subject will receive atx2417 and 1 subject will receive placebo) will be dosed on day 1 and the remaining 6 subjects will be dosed at least 24 hours later. safety and pharmacokinetic observations will be made. there will be a minimum of two weeks between the first dosing day at each dose level. safety and atx2417 pharmacokinetic data will be reviewed prior to each dose escalation and, based on pharmacokinetic data, it is also possible to decrease the dose if the pharmacokinetic profile so indicates. this part will also include an assessment of the effect of a high fat breakfast on the absorption and pharmacokinetic profile of atx 2417, performed at a dose predicted to be associated with therapeutic plasma concentrations. part b following completion of part a, and selection of appropriate dose levels, part b will be performed. this will be a randomised, double blind, placebo controlled, parallel group study of up to two dose levels of atx2417 given once daily for eight days. in each cohort, six subjects will receive active compound and two will receive placebo in a randomised fashion. safety and pharmacokinetic observations will be made.

Eligibility criteria:
inclusion criteria: 1. healthy male subjects, any racial group 2. able to comply with the protocol 3. subjects with a body mass index (bmi) of 21-28 (bmi = body weight (kg) / (height (m)2) exclusion criteria: 1. a history of gastrointestinal disorder likely to influence drug absorption 2. receipt of any medication including over the counter preparations and vitamins within 14 days of the first dose of study drug with the exception of paracetamol up to a maximum of 2 g daily 3. evidence of clinically significant renal, hepatic, cardiovascular or metabolic dysfunction 4. a history of drug or alcohol abuse 5. inability to communicate well with the investigator (i.e., language problem, poor mental development or impaired cerebral function)

Keywords: allergy
a usability study of a smoking cessation decision aid in people with a recent first episode of psychosis

Conditions: Smoking; Psychosis

Summary: the investigators propose to recruit patients who have experienced a recent first episode of psychosis who have a chart diagnosis of schizophrenia, schizophrenifom, schizoaffective disorder, psychosis nos, or bipolar i disorder with psychotic features and self identify themselves as a current cigarette smoker. aiding this population with smoking cessation is crucial as the majority of people with schizophrenia spectrum disorders (50-90%) smoke, which is leading to early mortality. while these individuals can benefit from standard evidence-based treatment, these treatments are underutilized. web based programs, such as the edss and thetruth.com, can provide education and motivational tools to help people with a recent onset of psychosis use evidence-based smoking cessation treatments. this study aims to test these two web-based programs among young people with a recent episode of psychosis for usability and likeability and to explore whether use of these two programs will motivate users to seek smoking cessation treatment or to engage in other quitting behaviors in the month following use of the programs. information gathered from this proposal will be used to help the researchers decide whether either of these two programs will be reasonable to include in a larger study of a comprehensive treatment for individuals with first episode psychosis.


Eligibility criteria:
inclusion criteria: * patients with clinical diagnoses of schizophrenia, schizophrenifom, schizoaffective disorder, psychosis nos, or bipolar i disorder with psychotic features * diagnosed with one of above diagnoses within the past five years * ages 15-30 years old. * self-identified current cigarette smokers * 5th grade reading level * willing to be audio recorded. * willing and legally able to provide informed consent to participate in the study or have a guardian provide informed consent with assent of a minor exclusion criteria: * physically unable to use a computer with assistance.

Keywords: smoking cessation first episode psychosis electronic decision support system
implantation of bone marrow cells to treat avascular necrosis of femoral head (anfh)

Conditions: Avascular Necrosis of Femur Head

Summary: the purpose of this study is to compare the efficacy of autologous enriched bone marrow cell implantation combined with core decompression to single core decompression for the treatment of avascular necrosis of femoral head.


Eligibility criteria:
inclusion criteria: * femoral head necrosis patients * stage i/ii/iii (ficat) * age from 18 to 55 years * stop steroid treatment for minimal 6 months exclusion criteria: * age younger than 18 or older than 55 * any hemopathy * tumor * femoral head/neck fracture
stress management intervention in early stage cancer: randomized controlled trial

Conditions: Cancer; Stress, Psychological

Summary: the purpose with this study is to test the effect of an app for stress management among patients with a variety of cancer diagnoses.

a cancer diagnosis and subsequent treatment can be disruptive and traumatic, often accompanied by a multitude of stressors for the patients and their support network. uncertainty of outcome and invasive medical procedures with aversive side effects are not uncommon, and while people differ widely in how they experience and cope with such challenges, cancer related distress including anxiety, depression, worry and rumination is prevalent. with multiple domains of function impacted it is also not surprising that quality of life (qol) often is diminished. stress management interventions can facilitate adjustment to cancer, including reduced distress and improved quality of life. unfortunately, many people with cancer do not have the strength or opportunity to attend groups or in-person interventions. this study will therefore test the effect of an app for stress management among patients with different cancer diagnosis. the app contains 10 modules distributed over five weeks, focusing on education of different techniques for reduction of stress and stress reduction exercises. the app was tested in a feasibility pilot study among 25 patients with a variety of cancer diagnoses and is now being tested in a randomized controlled trial with a sample of 175 cancer survivors. the participants were randomly assigned to use the 10 module app or to a control group that receive treatment as usual, and will be followed with repeated measures over 12 months.

Eligibility criteria:
inclusion criteria: * patients diagnosed with cancer (all diagnosis). * maximum time since completed treatment at hospital: 12 months * patients are \> 18 years of age, able to write/read/speak norwegian and have their own smart phone or tablet exclusion criteria: • none

Keywords: stress management app
effect of pulsed magnetic field versus low level laser therapy on functional performance in children with juvenile idiopathic arthritis

Conditions: Juvenile Idiopathic Arthritis

Summary: the purpose of this study is to compare between the effect of pulsed magnetic field versus low level laser therapy on functional performance in children with juvenile idiopathic arthritis

this study directed to investigate effect of pulsed magnetic field versus low level laser therapy on functional performance in children with juvenile idiopathic arthritis children with juvenile idiopathic arthritis suffer from some problems such as pain, swelling and limited motion in knee joints here in this study i used these devices to help in solving these problems pain was measured by visual analogue scale swelling was measured by tape measurement and range of motion was measured by digital geniometre

Eligibility criteria:
inclusion criteria: * 1 confirmed diagnosis of juvenile idiopathic arthritis (jia). * 2 polyarticular onset of jia with bilateral involvement of the knee joint. * 3 age between 8 and 16 years * 4 stable conditions (i.e., receive stable doses of medications in the past three months). * 5 not participating in a regular exercise program in the past six months. exclusion criteria: * 1 fixed deformities * 2 history of joint surgery * 3 ankylosing or fractures * 4 bone destruction ( erosive changes of the knee joints ).
evaluation of intravenous laronidase pharmacokinetics before and after hematopoietic cell transplantation in patients with mucopolysaccharidosis type ih.

Conditions: Hematopoietic Cell Transplantation; Mucopolysaccharidosis Type I

Summary: this is a prospective, observational multicenter study to collect blood from patients with mucopolysaccharidosis type ih undergoing laronidase therapy and a stem cell transplant. sixteen patients will be enrolled over a 24 month period.


Eligibility criteria:
inclusion criteria: * between 0 to 3 years of age * meet protocol specific eligibility criteria for allogeneic hct for mps ih * planning to receive laronidase both pre and post-transplant in an inpatient setting as part of standard-of-care treatment. virtually all patients with mpsih being considered for transplantation at the university of minnesota are already receiving enzyme infusions, and it is standard practice to continue to give enzyme infusions to 8 weeks post-transplant. therefore, participation will not modify the treatment course. exclusion criteria: * patient's parent/ legal guardians are unable to provide informed consent.

Keywords: mps i hct
open label extension study of conatumumab and ganitumab (amg 479)

Conditions: Advanced Solid Tumors; Carcinoid; Colorectal Cancer; Locally Advanced; Lymphoma; Metastatic Cancer; Non-Small Cell Lung Cancer; Sarcoma; Solid Tumors

Summary: the purpose of this protocol is to allow continued treatment with conatumumab and/or ganitumab, with or without chemotherapy, to participants who completed a separate amgen-sponsored conatumumab or ganitumab study without disease progression whose previous studies were closed.


Eligibility criteria:
inclusion criteria: * to be enrolled in this study, subjects must be currently enrolled in a prior amgen-sponsored conatumumab or amg 479 study and are eligible according to the parent study to receive their next dose of conatumumab (with or without co-therapy), or amg 479 alone. subjects must have their eligibility assessed for this study and be enrolled within 30 days of their last treatment on the parent protocol exclusion criteria: * discontinued from a conatumumab study due to an adverse event considered by the investigator to be related to conatumumab treatment, including intolerance to conatumumab * subjects determined to have disease progression during their participation in the parent amgen study * woman or man with partner of childbearing potential not consenting to use adequate contraceptive precautions ie, double barrier contraceptive methods (eg, diaphragm plus condom), or abstinence during the course of the study and for 6 months after the last dose of protocol-specified therapy administration * subject is pregnant or breast feeding, or planning to become pregnant within 6 months after the last dose of protocol-specified therapy administration * male subject with a pregnant partner who is not willing to use a condom during treatment and for an additional 6 months after the last dose of protocol-specified therapy administration * subject has previously entered this study * subject will not be available for protocol required study visits, to the best of the subject and investigator's knowledge * subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or to comply with all required study procedures

Keywords: amg 655 amg 479 apoptosis monoclonal antibody tumor necrosis factor insulin-like growth factor bevacizumab modified folfox6 mfolfox6 folfox lymphoma trail receptor ganitumab conatumumab
lymphoma in the orbit

Conditions: Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma

Summary: imaging techniques have considerably improved over the last decades and ocular adnexal lymphomas (oals) nowadays can be detected. as major advances in immunophenotyping and molecular diagnostics in histology have been achieved offering an accurate diagnosis, the investigators would like to introduce that surgical biopsy of an orbital lymphoma becomes crucial for the possibility of a correct diagnosis and proper treatment. as radiotherapy accomplished great preciseness as well and oals respond excellently to radiation, this therapy should be the treatment of choice in local defined lymphomas instead of blind treatment with steroids. radiation results in great local control rates of 85% to 100% * trial with surgical intervention


Eligibility criteria:
inclusion criteria: - both genders * \>17 years of age * underwent biopsy of an ocular adnexal lymphoma between 01/2006 and 12/2010 at the university hospital zurich, division of ophthalmology * diagnosis histologically proven exclusion criteria: * less than 18 years of age * patient underwent no mri before surgery (biopsy)

Keywords: ocular adnexal lymphomas
initial positioning of left sided double lumen endobronchial tubes using peak inspiratory pressures difference between two lungs

Conditions: Thoracic Surgery

Summary: the purpose of this study is to investigate a performance of initial positioning of left sided double lumen endobronchial tubes using peak inspiratory pressures difference between two lungs.

if both lungs have relatively equal volumes and the double lumen tube is in a satisfactory position, peak inspiratory pressure between two lungs is similar or equal when each lumen is sequentially clamped while ventilating each lung with the same tidal volume. we are going to investigate a performance of this method by fiberoptic bronchoscopy view and depth of double lumen tube, and compare with an conventional auscultation method.

Eligibility criteria:
inclusion criteria: * asa physical status class i, ii * use of double lumen tube * normal preoperative pulmonary function study exclusion criteria: * copd * restrictive lung disease * caod * unstable hemodynamic status * peak inspiratory pressure \> 30 mm hg (two lung ventilation)
cmr or angiography for ffr-guided revascularisation

Conditions: STEMI

Summary: around 50% of patients that present with st elevation myocardial infarction (stemi) have residual disease in the non-culprit lesions. if the residual disease should be treated, what should guide intervention? fractional flow reserve (ffr) has been proposed as a guide for intervention, however new developments in cardiovascular magnetic resonance (cmr) allows for non-invasive ffr measurements. if ffr from cmr can predict physiological significant stenosis as good as ffr from invasive angiography, unnecessary invasive producers can be avoided in patients with stemi.

early reperfusion of epicardial coronaries is essential for salvage of ischemic myocardium, reducing both morbidity and mortality in patients with st elevation myocardial infarction (stemi). current european society of cardiology guidelines recommend percutaneous coronary intervention (pci) of the infarct related artery (ira) for patients presenting with stemi, with residual disease initially being treated conservatively. large meta-analyses of observational studies have shown that pci of the ira only results in a reduced mortality compared to full revascularization in patients with stemi and simultaneous multivessel disease. however, recent small randomized controlled trials indicate that full revascularization reduces morbidity, but have been underpowered to show any reduction in mortality. furthermore, physiological guidance of coronary intervention by fractional flow reserve (ffr) reduces mortality compared to angiography guided pci in both stable angina and non-stemi (nstemi). however, if performing full revascularization guided by ffr in patients with stemi improves clinical outcome, compared to initial conservative approach is not known. assessment of myocardial perfusion in rest and during pharmacological stress is widely used for non-invasive diagnosis of myocardial ischemia, where cardiovascular magnetic resonance (cmr) has a high diagnostic accuracy. newly developed first pass perfusion imaging with cardiovascular magnetic resonance (cmr) allows for quantification of myocardial perfusion, and cmr derived ffr. however, it is currently not known if ffr from cmr and invasive angiography correlate with each other. if ffr from cmr can predict physiological significant stenosis as good as ffr from invasive angiography, unnecessary invasive producers can be avoided in patients with stemi.

Eligibility criteria:
inclusion criteria: * patients included in the active arm of full revasc, that has not undergone invasive ffr, and give written informed consent. exclusion criteria: * asthma/chronic obstructive pulmonary disease, systolic blood pressure under 90 mmhg, bradycardia (less than 45 beats/min), persistent second or third atrioventricular-block, sick sinus syndrome, long qt syndrome, atrial fibrillation, severe aortic stenosis, severe heart failure (nhya class iii-iv), metallic implants, kidney failure (less than 30 ml/min/1.73 square meters body surface area), current treatment with the drugs persantin, theophyllamin or fevarin.
pooled analysis of methodologically harmonized pragmatic randomized trials of high-dose vs. standard-dose influenza vaccine against severe clinical outcomes

Conditions: Influenza

Summary: this prespecified analysis will pool the datasets from two pragmatic randomized trials evaluating the relative vaccine effectiveness of high-dose vs. standard-dose influenza vaccine against severe clinical outcomes: the danflu-2 (a pragmatic randomized trial to evaluate the effectiveness of high-dose quadrivalent influenza vaccine vs. standard-dose quadrivalent influenza vaccine in older adults) trial and the galflu (pragmatic randomized trial to evaluate the effectiveness of high-dose quadrivalent influenza vaccine vs. standard-dose quadrivalent influenza vaccine in adults aged 65 to 79 years in galicia, spain) trial. the purpose of the pooled analysis is to ensure adequate statistical power for evaluating relative vaccine effectiveness against severe clinical outcomes and to increase generalizability of the results by combining data from two countries.


Eligibility criteria:
inclusion criteria: * pragmatic trials conducted to estimate the relative vaccine effectiveness of high-dose influenza vaccine compared with standard-dose influenza vaccine using the danflu-2 protocol or a protocol developed based on the danflu-2 protocol exclusion criteria: * low data quality * influenza circulation threshold was not met in any of the study seasons * severe under-enrollment in all seasons

Keywords: influenza vaccination pragmatic registry pneumonia respiratory cardiovascular meta-analysis